Donnerstag, 28. Januar 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 

JOURNAL ONKOLOGIE – STUDIE

VESTIGE Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Rekrutierend

NCT-Nummer:
NCT03443856

Studienbeginn:
Juli 2019

Letztes Update:
02.09.2020

Wirkstoff:
Nivolumab and Ipilimumab

Indikation (Clinical Trials):
Recurrence

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
Phase 2

Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC

Collaborator:
-

Studienleiter

Florian Lordick
Study Chair
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany
Maren Knoedler
Study Chair
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany
Elizabeth Smyth
Study Chair
Cambridge University Hospital NHS - Cambridge, UK

Kontakt

Studienlocations (3 von 21)

SLK-Kliniken Heilbronn
Heilbronn
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Rambam Health Care Campus, Oncology Institute
Haifa
IsraelRekrutierend» Google-Maps
Rabbin Medical Centre - Tel Aviv
Tel Aviv
IsraelNoch nicht rekrutierend» Google-Maps
Azienda Ospedaliera a Papa Giovanni XXIII
Bergamo
ItalyNoch nicht rekrutierend» Google-Maps
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Napoli
ItalyRekrutierend» Google-Maps
Oslo University Hospital - Ullevaal Hospital
Oslo
NorwayRekrutierend» Google-Maps
Maria Sklodowska-Curie Memorial Cancer Centre
02 781 Warsaw
PolandRekrutierend» Google-Maps
Institut Catalan d'Oncologia - ICO Badalona
Badalona
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario de Valencia
Valencia
SpainRekrutierend» Google-Maps
University Hospitals Birmingham NHS Foundation Trust
Birmingham
United KingdomNoch nicht rekrutierend» Google-Maps
Cambridge University Hospital NHS
Cambridge
United KingdomRekrutierend» Google-Maps
University College London Hospitals NHS Foundation Trust
London
United KingdomNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection.

Other study objectives:

- To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the study

- To correlate nutritional status assessment on outcomes and quality of life of patients

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically proven gastric, lower esophageal or GE-junction adenocarcinoma (Siewert I-III)

- Subjects must have completed pre-operative chemotherapy with a fluoropyrimidine-platinum containing regimen and macroscopically complete surgery prior to randomization

- Minimal duration of neoadjuvant chemotherapy should be 6 weeks, maximum 12 weeks.

- Total or distal gastrectomy with D2 lymphadenectomy according to ESMO guidelines should have been completed for gastric and junctional Siewert type III cancers. Ivor Lewis or McKeown oesophagectomy with two field lymphadenectomy should have been performed for junctional Siewert type I cancers. For Siewert type II cancers either total gastrectomy with D2-lymphadenectomy or oesophagectomy with two field lymphadenectomy should have been completed. Open, minimal invasive or hybrid surgical approaches are acceptable as long as the requirements above are fulfilled.

- Regardless of the type of surgery a minimum of 15 lymph nodes should have been resected and examined.

- Recovered from surgery and fit for study treatment as assessed by a multidisciplinary team. Surgery should have been completed 2 to 3 months before randomization.

- ypN1-3 status according to current (8th) version of TNM classification system. In case of an ypN0 status patients must meet the inclusion criterion of R1 resection.

- R0 or R1 resection according to current (8th) version of TNM classification system. In case of R0 resection, patients must meet the inclusion criterion of ypN1-3

- WHO performance status score of 0 or 1

- Age ≥ 18 years

- Adequate organ function assessed within 7 days before randomization:

- White blood cell count (WBC) > 2 x 109/L

- Absolute neutrophil count (ANC) > 1.5 x 109/L

- Platelets ≥ 100 x 109/L

- Hemoglobin ≥ 9 g/dL

- Measured/calculated creatinine clearance ≥ 60 mL/min (according to Cockroft-Gault formula).

- Total bilirubin within normal limits (if the patient has documented Gilbert's disease ≤ 1.5 * ULN or direct bilirubin ≤ ULN)

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5ULN

- Cardiac assessment by 12 Lead ECG and if clinically indicated, cardiac function assessment (using either echocardiography or MUGA scan)

- All toxicities (exception alopecia) attributed to prior anti-cancer therapy must have resolved to grade 1 (NCI CTCAE version 4) or baseline before administration of study drug.

- Women of childbearing potential (WOCBP*) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (HCG)) within 24 hours prior to randomization

- Men who are sexually active with an WOCBP must adhere to contraception (condom) during the study and for a period of 7 months after the last dose of the study treatment in the experimental arm and 6 months in the control arm.

- Patients of childbearing / reproductive potential should use highly effective method of birth control measures during the study treatment period and for at least 5 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

- Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.

- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

- R2 resection status

- M1 stage according to current (8th) version of TNM classification system

- Patients who have undergone complete resection of metastases

- Impaired renal, hepatic, cardiac, pulmonary or endocrine status that compromises the eligibility of the patient for postoperative chemotherapy or immunotherapy

- Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious cardiac arrhythmia requiring medication

- Subjects with previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry. Adequately treated cervical carcinoma in situ, and localized non-melanoma skin cancer are no exclusion criteria, regardless of timepoint of diagnosis.

- Subjects with active, known, or suspected infectious or autoimmune disease

- Patients who have received antibiotics within the last 14 days before randomization are excluded.

- Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll

- Subjects with a condition requiring systemic treatment with either corticosteroids (≥ 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration

- Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

- Subjects with > Grade 1 peripheral neuropathy

- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

- Prior or concomitant treatment with radiotherapy/radiochemotherapy

- Any positive test result for HBV or HCV indicating acute or chronic infection

- Known history of HIV or known AIDS and, if required by local practice or positive HIV testing at screening

- Known uncontrollable hypersensitivity to the components of cisplatin/oxaliplatin, fluorouracil (5-FU) or capecitabine, epirubicine or docetaxel

- Known dihydropyrimidine dehydrogenase (DPD) deficiency

- Ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine.

Studien-Rationale

Primary outcome:

1. Disease free survival (DFS) (Time Frame - 22 months after last patient in):
Disease free survival is defined as the time interval between randomization and the date of disease recurrence or death from any cause, whichever comes first. Patients alive with no disease recurrence are censored at the date of the last follow-up examination. randomization and the date of disease recurrence or death from any cause, whichever comes first.



Secondary outcome:

1. Overall survival (OS) (Time Frame - 5 years after last patient in):
Overall survival is defined as the time interval between the date of randomization and the date of death from any cause. Patients who are still alive when last traced are censored at the date of last follow up.

2. Loco-regional failure rates (Time Frame - 5 years after last patient in):
Local recurrence is defined as evidence of tumor in the anastomotic area. Regional recurrence is defined as evidence of tumor in the locoregional lymph nodes or other surrounding structures apart from the anastomotic site. Death in absence of loco-regional failure will be considered as a competing risk in the estimation of the cumulative incidence of loco-regional failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination.

3. Distant failure rates (Time Frame - 5 years after last patient in):
The diagnosis of distant recurrence requires imaging confirmed by pathology. Once recurrence is confirmed, the date of recurrence is the first date when recurrence was suspected. Distant recurrence is defined as recurrence not considered as local or regional.Death in absence of distant failure will be considered as a competing risk in the estimation of the cumulative incidence of distant failures. Patients who have not had any such event at the time of data analysis will be censored at the date of the last follow-up examination

4. Rate of adverse events according to NCI-CTCAE (Time Frame - 5 years after last patient in):
All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events. AEs will be collected at baseline from randomization. Only the worst grade per CTCAE category will be recorded per cycle. All adverse events must be followed until resolution or stabilization. Adverse Events of Special Interest for ipilimumab and nivolumab requiring a close follow-up were identified as a result of signals observed from previous studies involving the protocol treatments. These events require a close follow-up

5. Quality of life assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 (Time Frame - questionnaires will be completed at baseline, week 6, 3 months, 6 months, 9 months, 12 months, 15 months):
Quality of life will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3. These include five functional scales (physical, role, emotional, social, and cognitive), three symptom (fatigue, nausea and vomiting and pain) and a global health status/QoL scale and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). The primary HRQoL endpoints that are considered relevant for this study are global health status/QoL and physical functioning.A difference of 10 points on the 100-point QLQ-C30 scale between the two arms will be considered as clinically relevant

Studien-Arme

  • Other: chemotherapy arm
    Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
  • Experimental: immunotherapy arm
    Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.

Geprüfte Regime

  • Nivolumab and Ipilimumab:
    Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
  • chemotherapy:
    Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie